MORF News and Press, Morphic Holding Inc. From 06/06/23

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies He...

Morphic Holding, Inc. (NASDAQ: MORF) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.31% on the day to $57.79. Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, c...

WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in a Fireside Chat a...

WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous findings and add new support to mechanistic understanding of the molecule’s...

Morphic Holding, Inc. (NASDAQ: MORF) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.46% on the day to $58.23. Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, ...

WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the closing of an underwritten public offering of 6,133,33...

2023-05-03 04:42:30 ET Biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, Morphic ( NASDAQ: MORF ) prices underwritten public offering of 5.33M shares at a price to the public of $45.00 per share. ...

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an underwritten public offering of 5,333,334 shares of...

2023-05-02 16:19:46 ET Morphic Holding ( NASDAQ: MORF ) on Tuesday announced a proposed underwritten public offering of its common stock. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its shares. All of the shares o...

2023-04-29 08:25:00 ET 89bio (NASDAQ: ETNB) , Karuna Therapeutics (NASDAQ: KRTX) , and Morphic Therapeutics (NASDAQ: MORF) are clinical-stage biotech companies that make attractive buyout targets. Their financial positions may not be great, as they all have littl...